Prosecution Insights
Last updated: November 20, 2026
Application No. 18/267,835

POLYPEPTIDE

Final Rejection §102§103§112
Filed
Jun 16, 2023
Priority
Dec 16, 2020 — GB 2019879.2 +1 more
Examiner
XIAO, YAN
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ucl Business Ltd.
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
521 granted / 772 resolved
+7.5% vs TC avg
Strong +53% interview lift
Without
With
+52.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
51 currently pending
Career history
810
Total Applications
across all art units

Statute-Specific Performance

§101
4.8%
-35.2% vs TC avg
§103
26.4%
-13.6% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
27.0%
-13.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 772 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 2. The amendment filed 10/08/2026 is acknowledged and has been entered. Claims 1, 4 and 6 have been amended. Claims 3 and 15 have been canceled. Upon review and reconsideration HIV-1 Nef (SEQ ID NO: 13) will be rejoined with HCMV US11 (SEQ ID NO: 1) for examination. 3. Claims 1, 4, 6, 9, 12, 17-19, 21-22, 27, 29-30, 35, 39-40 and 44-45 are pending in the application. Claims 18-19, 21-22, 27, 30, 35, 39-40 and 44-45 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 03/30/2026. 4. Claims 1, 4, 6, 9, 12, 17 and 29 have been examined. Grounds of Objection and Rejection Withdrawn 5. Unless specifically reiterated below, Applicant’s amendment and/or arguments have obviated or rendered moot the grounds of objection and rejection set forth in the previous Office action mailed 06/08/2026. Grounds of Rejection Maintained Claim Rejections - 35 USC § 112 6. The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. 7. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. 8. Claims 1, 4, 6, 9, 12, 17 and 29 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a “written description” rejection. The considerations that are made in determining whether a claimed invention is supported by an adequate written description are outlined by the published Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, para. 1, ``Written Description'' Requirement (Federal Register; Vol. 66, No. 4, January 5, 2001; The 2015 Written Description Workshop materials; hereinafter “Guidelines”). These guidelines state that rejection of a claim for lack of written description, where the claim recites the language of an original claim should be rare. Nevertheless, these guidelines further state, “the issue of a lack of written description may arise even for an original claim when an aspect of the claimed invention has not been described with sufficient particularity such that one skilled in the art would recognize that the applicant has possession of the claimed invention” (Id. at 1105). The “Guidelines” continue: The claimed invention as a whole may not be adequately described if the claims require an essential or critical feature which is not adequately described in the specification and which is not conventional in the art or known to one of ordinary skill in the art. This problem may arise where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. A lack of adequate written description issue also arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. With further regard to the proposition that, as original claims, the claims themselves provide in haec verba support sufficient to satisfy the written description requirement, the Federal Circuit has explained that in ipsis verbis support for the claims in the specification does not per se establish compliance with the written description requirement: Even if a claim is supported by the specification, the language of the specification, to the extent possible, must describe the claimed invention so that one skilled in the art can recognize what is claimed. The appearance of mere indistinct words in a specification or a claim, even an original claim, does not necessarily satisfy that requirement. The disclosure must allow one skilled in the art to visualize or recognize the identity of the subject matter purportedly described. Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997). See also: University of Rochester v. G.D. Searle & Co., 69 USPQ2d 1886 1892 (CA FC 2004). Thus, an original claim may provide written description for itself, but it must still be an adequate written description, which establishes that the inventor was in possession of the invention. In this instance, claims 1, 4, 6, 9, 12, 17 and 29 are drawn to a sequence having at least 90% identical to SEQ ID NO: 1,3,5,7,9,11,13,15,17 or 43. Claim 6 is drawn to a sequence having at least 80% identical to SEQ ID NO: 19, 21, 23, or 42. Specification teaches anti-CD3 scFv-US11 fusion protein, anti-CD19 CAR-US11 fusion protein, anti-CD3 scFv-E19 fusion protein and anti-CD3 VHH-US11 fusion protein; see Examples 1-4. Specification teaches SEQ ID NOs: 1,3,5,7,9,11,13,15,17, 19,21,23 and 42-43; see pages 6-11 and 14-16. Thus, the claims are drawn to a genus of sequences having at least 80% or 90% identical to SEQ ID NOs: 1,3,5,7,9,11,13,15,17, 19,21,23 and 42-43. Although the specification teaches anti-CD3 scFv-US11 fusion protein, anti-CD19 CAR-US11 fusion protein, anti-CD3 scFv-E19 fusion protein and anti-CD3 VHH-US11 fusion protein, and SEQ ID NOs: 1,3,5,7,9,11,13,15,17, 19, 21,23 and 43. However, the specification does not teach a genus of sequences having at least 80% or 90% identical to SEQ ID NOs: 1,3,5,7,9,11,13,15,17, 19,21,23 and 42-43 would have the same activity as said SEQ ID NOs. Given the fact that the claims are drawn to a genus of sequences having at least 80% or 90% identical to SEQ ID NOs: 1,3,5,7,9,11,13,15,17, 19,21,23 and 42-43, which have no particular function or activity, there is no correlation between any one particularly identifying structural feature and any one particularly identifying functional feature. Consequently, it is submitted that the skilled artisan could not immediately envision, recognize or distinguish at least a substantial number of sequences to which the claims are directed. Although the specification teaches the SEQ ID NOs, the SEQ ID NOs are not reasonably representative of the plurality of sequences having at least 80% or 90% identical to the SEQ ID NOs. This is largely because each sequence has substantially varied structure and need not have any particular function or activity. Guidelines states, “[p]ossession may be shown in a variety of ways including description of an actual reduction to practice, or by showing the invention was ‘ready for patenting’ such as by disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention” (Id. at 1104). “Guidelines” further states, “[f]or inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus” (Id. at 1106); accordingly, it follows that an adequate written description of a genus cannot be achieved in the absence of a disclosure of at least one species within the genus. Moreover, because the claims encompass a genus of sequences having at least 80% or 90% identical to SEQ ID NOs: 1,3,5,7,9,11,13,15,17, 19,21,23 and 42-43, which vary both structurally and functionally, an adequate written description of the claimed invention must include sufficient description of at least a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics sufficient to show that Applicant was in possession of the claimed genus. In this instance, factual evidence of an actual reduction to practice has not been disclosed by Applicant in the specification; Applicant has not shown the invention was “ready for patenting” by disclosure of drawings or structural chemical formulas that show that the invention was complete; and Applicant has not described distinguishing identifying characteristics sufficient to show that Applicant was in possession of the claimed invention at the time the application was filed. Thus, it is submitted that the instant claims, and the disclosure describing the claimed subject matter, fails to satisfy the written description requirement set forth under 35 U.S.C. § 112, first paragraph. The Applicant’s arguments: Amended claim 1 specifies: wherein the first domain comprises a sequence having at least 90% identity to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 43. Response to Arguments Applicant’s arguments have been carefully considered but not found persuasive for the following reasons: Although claim 1 has been amended as “a sequence having at least 90% identity to SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 43”; however, as set forth above a genus of sequences having at least 90% identical to SEQ ID NOs: 1,3,5,7,9,11,13,15,17 and 43 would have no particular function or activity. Therefore, the rejection is maintained for reasons of record. New Grounds of Rejection Claim Rejections - 35 USC § 102 9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. 10. Claims 1, 4, 9, 12, 17 and 29 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Banchereau et al. (WO 2010/009346, published on 21 January 2010, IDS). Claims 1, 4, 9, 12, 17 and 29 are herein drawn a polypeptide comprising:(i) a first domain which is capable of downregulating cell surface expression of an MHC class I molecule; and(ii) a second domain which is capable of binding a component of T-cell receptor (TCR)/CD3 complex, wherein the first domain comprises a sequence having at least 90% identity to SEQ ID NO: 13, wherein the second domain is an antibody or a fragment thereof. Banchereau et al. teach an engineered HIV Nef antigen (SEQ ID NO: 10) is attached to an anti-CD3 antibody via a linker to form an antibody-antigen complex; see entire document, e.g., page 4-lines 3-25, page 22-lines 19-36, claims 13, 22, 32 and 40. SEQ ID NO: 10 of Banchereau et al. is 91.7% identical with the instant claimed SEQ ID NO: 13; see below sequence alignment-1. Claim Rejections - 35 USC § 103 11. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 12. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 13. Claims 1, 4, 9, 12, 17 and 29 are rejected under 35 U.S.C. 103 as being unpatentable over Banchereau et al. (WO 2010/009346, published on 21 January 2010, IDS) in view of Jennifer et al. (WO 2020102709, published on 05/22/2020) (of record). Claims 1, 4, 9, 12, 17 and 29 are herein drawn a polypeptide comprising:(i) a first domain which is capable of downregulating cell surface expression of an MHC class I molecule; and(ii) a second domain which is capable of binding a component of T-cell receptor (TCR)/CD3 complex, wherein the first domain comprises a sequence having at least 90% identity to SEQ ID NO: 1 or 13, wherein the second domain is an antibody or a fragment thereof. Banchereau et al. teach an engineered HIV Nef antigen (SEQ ID NO: 10) is attached to an anti-CD3 antibody via a linker to form an antibody-antigen complex; see entire document, e.g., page 4-lines 3-25, page 22-lines 19-36, claims 13, 22, 32 and 40. SEQ ID NO: 10 of Banchereau et al. is 91.7% identical with the instant claimed SEQ ID NO: 13; see below sequence alignment-1. Banchereau et al. do not teach the virus antigen is HCMV US11 (SEQ ID NO: 1). However, this deficiency is remedied by Jennifer et al. Jennifer et al. teach MHC class I antigen presentation pathway inhibitor polypeptides include HCMV US11, HCMV US2, HCMV US3, E19, Nef, KSHV K3, KSHV K5, and HBV; see entire document, e.g., pages 35-40, 48-50. Jennifer et al. teach US 11 polypeptide comprising the amino acid sequence SEQ ID NO: 962; see page 37. SEQ ID NO: 962 of Jennifer et al. is 99.6% identical to instant claimed SEQ ID NO: 1; see below sequence alignment-2. It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of the references so as to have a polypeptide comprises a first domain comprising US11 and a second domain binds to CD3. One would have been motivated to do so because Banchereau et al. teach an engineered HIV Nef antigen (SEQ ID NO: 10) is attached to an anti-CD3 antibody via a linker to form an antibody-antigen complex; Jennifer et al. teach MHC class I antigen presentation pathway inhibitor polypeptides include HCMV US11, HCMV US2, HCMV US3, E19, Nef, KSHV K3, KSHV K5, and HBV. Thus, one of ordinary skill in the art would have a reasonable expectation of success that by combining the teachings of the references so as to substitute HIV Nef of Banchereau et al. for another virus e.g., HCMV US11 of Jennifer et al. to arrive the instant claimed invention, because simple substitution of HIV Nef virus of Banchereau et al. for another virus e.g., HCMV US11 of Jennifer et al. would obtain predictable results. Given the examination guidelines for determining obviousness under 35 U.S.C. 103 in view of the Supreme Court decision in KSR International Co. V. Teleflex Inc. 82 USPQ2d 1385 (2007) and the Examination Guidelines set forth in the Federal Register (Vol. 72, No. 195, October 10, 2007) and incorporated recently into the MPEP (Revision 9, March 2014), the following rationales to support rejection under 35 U.S.C. 103(a) are noted: A) Combining prior art elements according known methods to yield predictable results. B) Simple substitution of one known element for another to obtain predictable results. C) Use of known technique to improve similar devices (methods, or products) in the same way. D) Applying known technique to a known device (method, or product) ready for improvement to yield predictable results. E) “Obvious to try” --- choosing form a finite number of identified, predictable solutions, with a reasonable expectation of success. (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art. G) Some teachings, suggestion, or motivation in the prior art that would lead to one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. In this case, simple substitution of HIV Nef virus of Banchereau et al. for another virus e.g., HCMV US11 of Jennifer et al. would obtain predictable results. Obviousness is not the result of a rigid formula disassociated from the consideration of the facts of a case. Indeed, the common sense of those skilled in the art demonstrates why some combinations would have been obvious where others would not. See KSR International Co. V. Teleflex Inc. 82 USPQ2d 1385 (2007). From the combined teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Conclusion 14. No claim is allowed. 15. Applicant's amendment necessitated the new ground(s) of objection/rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. 16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YAN XIAO whose telephone number is (571)270-3578. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached on 571-270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YAN XIAO/Primary Examiner, Art Unit 1642 Sequence alignment-1 AXV47450 ID AXV47450 standard; protein; 690 AA. XX AC AXV47450; XX DT 15-APR-2010 (first entry) XX DE Antibody heavy chain-HIV nef antigen fusion protein, SEQ ID NO: 10. XX KW Nef protein; anti-hiv; antibody; antigen; fusion protein; heavy chain; KW hiv infection; immune stimulation; vaccine, antiviral. XX OS Homo sapiens. OS Human immunodeficiency virus. OS Synthetic. OS Unidentified. XX FH Key Location/Qualifiers FT Region 454..455 FT /note= "Linking restriction site region" FT Region 456..482 FT /note= "Flexible linker" FT Region 483..484 FT /note= "Linking restriction site region" FT Region 485..690 FT /note= "Nef consensus clade B region" XX CC PN WO2010009346-A2. XX CC PD 21-JAN-2010. XX CC PF 16-JUL-2009; 2009WO-US050903. XX PR 16-JUL-2008; 2008US-0081234P. XX CC PA (BAYU ) BAYLOR RES INST. XX CC PI Banchereau JF, Cobb A, Flamar A, Mead H, Montes M, Zurawski G; XX DR WPI; 2010-A90746/08. XX CC PT Increasing the effectiveness of antigen presentation by an antigen CC PT presenting cell by contacting the antigen presenting cell under CC PT conditions where an antibody-antigen complex is processed and presented CC PT for T cell recognition. XX CC PS Claim 11; SEQ ID NO 10; 70pp; English. XX CC The invention relates to a novel method of increasing the effectiveness CC of antigen presentation by an antigen presenting cell. The method CC comprises: isolating and purifying a dendritic cell (DC) specific CC antibody or its fragment to which an engineered Gag or Nef antigen is CC attached to form an antibody-antigen complex; and contacting the antigen CC presenting cell under conditions where the antibody-antigen complex is CC processed and presented for T cell recognition. Also claimed is a vaccine CC comprising: a DC-specific antibody or its fragment to which an engineered CC Cyclin D1 or Gag antigen is attached; a method for increasing the CC effectiveness of dendritic cells; an isolated and purified nucleic acid CC that encodes a polypeptide selected from any one of fully defined CC sequences selected from (AXV47441-AXV47445, AXV47447-AXV47463, AXV47471, CC or AXV47472) given in the specification. XX SQ Sequence 690 AA; Query Match 91.7%; Score 1035; Length 690; Best Local Similarity 88.3%; Matches 182; Conservative 15; Mismatches 9; Indels 0; Gaps 0; Qy 1 MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAATNAACAWLEA 60 ||||||| ||:||||||||||||||||| ||| ||||||||||||||||| || |||||| Db 485 MGGKWSKRSVVGWPTVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTAANNADCAWLEA 544 Qy 61 QEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGY 120 |||||||||| ||||||||||| |:||||||||||||||||:||:||||||||:|||||| Db 545 QEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEGLIYSQKRQDILDLWVYHTQGY 604 Qy 121 FPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKIEEANKGENTSLLHPVSLHGMDDPEREV 180 ||||||||||||:|||||||||:|||||||:|:||||:||| |||||:|||||||||||| Db 605 FPDWQNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMDDPEREV 664 Qy 181 LEWRFDSRLAFHHVARELHPEYFKNC 206 | |:|||||||||:||||||||:|:| Db 665 LVWKFDSRLAFHHMARELHPEYYKDC 690 Sequence alignment-2 BHU77556 ID BHU77556 standard; protein; 215 AA. XX AC BHU77556; XX DT 09-JUL-2020 (first entry) XX DE Therapeutic polypeptide delivering US11 polypeptide, SEQ ID 962. XX KW CRISPR-Cas system; US11 protein; genome editing; virus-like particle. XX OS Unidentified. XX CC PN WO2020102709-A1. XX CC PD 22-MAY-2020. XX CC PF 15-NOV-2019; 2019WO-US061778. XX PR 16-NOV-2018; 2018US-0768508P. PR 03-MAY-2019; 2019US-0843139P. PR 21-AUG-2019; 2019US-0889867P. XX CC PA (REGC ) UNIV CALIFORNIA. XX CC PI Doudna JA, Hamilton JR; XX DR WPI; 2020-439275/046. DR GENBANK; APG57339. XX CC PT New nucleic acid comprising nucleotide sequence encoding virus-like CC PT particle comprising fusion polypeptide, therapeutic polypeptide, and CC PT heterologous protease cleavage sites, used to make virus-like particle. XX CC PS Disclosure; SEQ ID NO 962; 323pp; English. XX CC The present invention relates to a method for making a virus-like CC particle (VLP). The VLP comprising a therapeutic polypeptide. The CC invention further relates to: a nucleic acid comprising a nucleotide CC sequence encoding a VLP comprising a fusion polypeptide; a system; a CC eukaryotic cell; and a method for delivering a therapeutic polypeptide to CC a target cell. The fusion polypeptide comprises a retroviral GAG CC polyprotein, a therapeutic polypeptide and heterologous protease cleavage CC sites corresponds to SEQ ID NOs: 854, 883-890 (see BHU77448, BHU77477- CC BHU77484). The invention also relate to compositions and methods for CC delivering CRISPR/Cas effector polypeptides and CRISPR/Cas system useful CC for genome editing. XX SQ Sequence 215 AA; Query Match 99.6%; Score 1163; Length 215; Best Local Similarity 99.5%; Matches 214; Conservative 0; Mismatches 1; Indels 0; Gaps 0; Qy 1 MNLVMLILALWAPVAGSMPELSLTLFDEPPPLVETEPLPPLSDVSEYRVEYSEARCVLRS 60 ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| Db 1 MNLVMLILALWAPVAGSMPELSLTLFDEPPPLVETEPLPPLPDVSEYRVEYSEARCVLRS 60 Qy 61 GGRLEALWTLRGNLSVPTPTPRVYYQTLEGYADRVPTPVEDVSESLVAKRYWLRDYRVPQ 120 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 61 GGRLEALWTLRGNLSVPTPTPRVYYQTLEGYADRVPTPVEDVSESLVAKRYWLRDYRVPQ 120 Qy 121 RTKLVLFYFSPCHQCQTYYVECEPRCLVPWVPLWSSLEDIERLLFEDRRLMAYYALTIKS 180 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 121 RTKLVLFYFSPCHQCQTYYVECEPRCLVPWVPLWSSLEDIERLLFEDRRLMAYYALTIKS 180 Qy 181 AQYTLMMVAVIQVFWGLYVKGWLHRHFPWMFSDQW 215 ||||||||||||||||||||||||||||||||||| Db 181 AQYTLMMVAVIQVFWGLYVKGWLHRHFPWMFSDQW 215
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
Jun 08, 2026
Non-Final Rejection mailed — §102, §103, §112
Oct 08, 2026
Response Filed
Nov 13, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797483
PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LIPID-PHOTOTHERMAL NANOPARTICLE HAVING ANTIBODY BOUND TO SURFACE
3y 7m to grant Granted Nov 17, 2026
Patent 12797481
DEVELOPMENT OF DRUG THERAPEUTIC AGENT CONTAINING ADAPTOR AND USE THEREOF
3y 8m to grant Granted Nov 17, 2026
Patent 12780920
NOVEL AGENTS AND USES THEREOF
4y 5m to grant Granted Nov 03, 2026
Patent 12780934
ANTIBODIES TO CANCER GLYCOSYLATION AND USES THEREOF
3y 3m to grant Granted Nov 03, 2026
Patent 12773405
COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITORS
1y 6m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+52.7%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 772 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month